Phaseline

Companies › Outlook Therapeutics

Outlook Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Ophthalmology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Bevacizumab (ONS-5010)
Vascular endothelial growth factor A inhibitor
VEGFAPhase 3Age-Related Macular DegenerationDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05112861Bevacizumab (ONS-5010)Phase 3Age-Related Macular DegenerationOphthalmologyDec 2027

From the company's SEC filings

Cash of $11m on 2026-06-30; operating cash outflow about $59m a year; runway about 2 months at that burn, to Sep 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Complete response letters from FDA

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

VEGFA (1)

Companies with the same targets

Roche Jiangsu Simcere Pharmaceutical Chengdu Origen Biotechnology Biotheus AstraZeneca Prestige Biopharma Avirmax Biopharma Eli Lilly 4D Molecular Therapeutics PPD Development, LP

Companies built like this

BioDlink Biopharm Innostellar Biotherapeutics EyePoint Pharmaceuticals Adverum Biotechnologies Alvotech Swiss

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.